PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy

PIK3CA gain-of-function mutations are among the most common alterations in human solid cancers. Through the use of stimulation-induced functional T cell receptor (TCR) sequencing (SIFT-seq), a panel of TCRs that bind a mutant PI3K alpha shared neoantigen was identified, including a potential clinical candidate that engages cancer cells via a distinctive CDR3 beta loop.

Automated summary

PIK3CA gain-of-function mutations are common in human solid cancers. Using SIFT-seq, a panel of TCRs that bind a mutant PI3K alpha shared neoantigen was identified, including a potential clinical candidate that interacts with cancer cells through a distinctive CDR3 beta loop.